article Open AccessTop 1% cited

Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study

The Lancet Oncology · 2015 · Vol. 16(2) · pp. 187–199

Jeffrey D. Bradley✉(Washington University in St. Louis)Rebecca Paulus(RTOG Foundation)Ritsuko Komaki(The University of Texas MD Anderson Cancer Center)Gregory A. Masters(Christiana Care Health System)George Blumenschein(The University of Texas MD Anderson Cancer Center)Steven E. Schild(Mayo Clinic in Arizona)Jeffrey A. Bogart(SUNY Upstate Medical University)Chen Hu(RTOG Foundation)Kenneth Forster(Moffitt Cancer Center)Anthony M. Magliocco(Moffitt Cancer Center)Vivek S. Kavadi(Texas Oncology)Yolanda I. Garces(Mayo Clinic)Samir Narayan(Michigan Cancer Research Consortium)Puneeth Iyengar(The University of Texas Southwestern Medical Center)Clifford G. Robinson(Washington University in St. Louis)Raymond B. Wynn(Shadyside Hospital)Christopher D. Koprowski(Christiana Care Health System)Joanne Meng(Ottawa Hospital)Jonathan J. Beitler(Emory University)Rakesh GaurWalter J. Curran(Emory University)Hak Choy(The University of Texas Southwestern Medical Center)

View via DOI Publisher page

Lung Cancer Diagnosis and Treatment Lung Cancer Treatments and Mutations Head and Neck Cancer StudiesCarboplatinMedicineCetuximabPaclitaxelOncologyRadiation therapyStage (stratigraphy)Internal medicineLung cancerChemotherapy

MeSH terms

CetuximabAdenocarcinomaAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCombined Modality TherapyFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMiddle Aged